How to Save on Ozempic and Wegovy in 2026

Semaglutide medications have transformed diabetes and weight management, but the price tag remains a major barrier. Here is a practical guide to every savings option available right now.

What Ozempic and Wegovy Actually Cost

Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for weight management) are both manufactured by Novo Nordisk and are among the most expensive commonly prescribed medications in America. The list price for Ozempic runs approximately $900 to $1,000 per month, while Wegovy, which is dosed higher for weight loss, lists at approximately $1,300 per month. These are the prices you would face if you walked into a pharmacy without insurance and without any discount program.

To put that in context, a year of Ozempic at list price costs roughly $11,000, and a year of Wegovy costs about $16,000. These are not prices most Americans can absorb out of pocket, which is why understanding every available savings pathway matters so much. The gap between what these drugs cost at list price and what patients can actually afford has created an entire ecosystem of savings programs, workarounds, and controversies.

Novo Nordisk Savings Programs

Novo Nordisk, the manufacturer of both Ozempic and Wegovy, offers several savings programs that can dramatically reduce out-of-pocket costs for eligible patients. The Ozempic Savings Card is available to commercially insured patients and can reduce the copay to as low as $25 per month for up to 24 months. The card is not available to patients with government insurance (Medicare, Medicaid, or Tricare), and it requires that your insurance already covers Ozempic.

For Wegovy, Novo Nordisk has offered a similar savings card program, though the specifics and availability have shifted over time as the company has managed supply constraints. Check the official Wegovy website for the most current program details, as the terms change periodically.

For patients who are uninsured or who cannot afford their medication even with insurance, Novo Nordisk's Patient Assistance Program (PAP) provides the medication at no cost to qualifying patients. Eligibility is typically based on income (generally at or below 400% of the federal poverty level) and lack of prescription drug coverage. The application process requires documentation of income and a prescription from your doctor, and approval can take several weeks.

Insurance Coverage and Prior Authorization

Insurance coverage for semaglutide medications varies enormously by plan. Most commercial insurance plans cover Ozempic for type 2 diabetes, though many require prior authorization. This means your doctor needs to submit documentation showing that you meet certain criteria, such as having tried and failed other diabetes medications first, or having an A1C above a specific threshold. The prior authorization process can take a few days to a few weeks, and not all requests are approved on the first attempt.

Coverage for Wegovy (weight management) is more complicated. Many insurance plans exclude weight-loss medications entirely, and even plans that cover Wegovy often impose strict criteria: a BMI of 30 or higher (or 27 with a weight-related condition), documentation of failed diet and exercise attempts, and sometimes requirements to try older, cheaper weight-loss medications first. Medicare Part D does not cover Wegovy for weight loss, though there has been ongoing legislative discussion about changing this.

If your insurance denies coverage, do not give up after the first rejection. Ask your doctor to file an appeal, and consider requesting a peer-to-peer review where your doctor speaks directly with the insurance company's medical reviewer. Many initial denials are overturned on appeal, especially when accompanied by thorough clinical documentation.

The Compounding Pharmacy Controversy

One of the most discussed developments in the semaglutide market has been the rise of compounding pharmacies offering semaglutide at dramatically lower prices, often $200 to $500 per month. Compounding pharmacies are permitted under FDA regulations to produce compounded versions of drugs that are on the FDA's shortage list. Semaglutide has appeared on that list periodically due to overwhelming demand, which opened the door for compounders to legally produce their own versions.

However, this area comes with significant caveats. Compounded semaglutide is not FDA-approved and does not go through the same rigorous testing as commercially manufactured Ozempic or Wegovy. The quality, purity, and potency can vary between compounding pharmacies. Novo Nordisk has actively fought against compounders, arguing that the shortage has been resolved and that compounded versions should no longer be permitted. The regulatory landscape here is shifting and uncertain.

If you are considering a compounding pharmacy, research the pharmacy carefully. Look for pharmacies that are accredited by the Pharmacy Compounding Accreditation Board (PCAB) and that provide certificates of analysis for their products. Discuss the option with your doctor, who can help you weigh the cost savings against the potential risks.

Telehealth Options and Future Generics

Several telehealth companies have built services around prescribing and delivering GLP-1 medications, including semaglutide. Companies like Ro, Hims/Hers, and Calibrate offer online consultations, prescriptions, and sometimes their own compounded versions of semaglutide at lower prices than retail. These services can be convenient and sometimes more affordable, but the same cautions about compounded medications apply. Make sure you understand exactly what product you are receiving and from which pharmacy it is being dispensed.

Looking ahead, the question everyone wants answered is when a true FDA-approved generic semaglutide will be available. Novo Nordisk's patents on semaglutide extend through the late 2020s and into the 2030s, depending on the specific patent and legal challenges. Generic competition is not expected to arrive before 2031 at the earliest, and potentially later. When generics do arrive, they will likely bring prices down substantially, as has happened with virtually every other blockbuster drug that has lost patent protection. But that timeline offers little relief to patients struggling with costs today.

What RxGator Shows for Brand Semaglutide

RxGator includes pricing for Ozempic and Wegovy from multiple sources, including pharmacy cash prices and available discount programs. While no comparison tool can make a $900 medication cheap, seeing the full range of prices across pharmacies can help you identify the best available option. Some pharmacies price these medications significantly lower than others, and the difference can amount to $100 or more per fill. For a medication this expensive, comparing prices is not optional; it is essential.